A University of Barcelona study, published in the Schizophrenia Bulletin, reveals a significant link between schizophrenia and impaired visual contrast sensitivity. This deficit, affecting the ability to distinguish light intensity and perceive shapes, may be rooted in disrupted glutamate neurotransmission. Researchers suggest contrast sensitivity testing could serve as a non-invasive biomarker for schizophrenia, though further research is needed to account for medication effects and attentional issues. The study, a meta-analysis of over 600 studies, found that people with schizophrenia have difficulty detecting light intensity differences. This visual impairment could potentially reflect underlying neurological dysfunction.

https://neurosciencenews.com/?s=A+University+of+Barcelona+study%2C+published+in+the+Schizophrenia+Bulletin%2C+reveals+a+significant+link+between+schizophrenia+and+impaired+visual+contrast+sensitivity.+This+deficit%2C+affecting+the+ability+to+distinguish+light+intensity+and+perceive+shapes%2C+may+be+rooted+in+disrupted+glutamate+neurotransmission.+Researchers+suggest+contrast+sensitivity+testing+could+serve+as+a+non-invasive+biomarker+for+schizophrenia%2C+though+further+research+is+needed+to+account+for+medication+effects+and+attentional+issues.+The+study%2C+a+meta-analysis+of+over+600+studies%2C+found+that+people+with+schizophrenia+have+difficulty+detecting+light+intensity+differences.+This+visual+impairment+could+potentially+reflect+underlying+neurological+dysfunction.

#Neuroscience #BrainHealth #CognitivePerformance